APLS Quote, Financials, Valuation and Earnings

Arvinas has a net margin of -17.11% compared to Apellis Pharmaceuticals's net margin of 43.91%. Apellis Pharmaceuticals's return on equity of -83.06% beat Arvinas's return on equity of -7.72%.

Apellis Pharmaceuticals has a consensus price target of $40.35, signalling upside risk potential of 124.29%. On the other hand Arvinas has an analysts' consensus of $22.42 which suggests that it could grow by 236.08%. Given that Arvinas has higher upside potential than Apellis Pharmaceuticals, analysts believe Arvinas is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Arvinas has a beta of 2.215, suggesting its more volatile than the S&P 500 by 121.499%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $212.5M, which are larger than Arvinas quarterly revenues of $188.8M. Apellis Pharmaceuticals's net income of -$36.4M is lower than Arvinas's net income of $82.9M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.85x versus 1.13x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Macrogenics has a net margin of -17.11% compared to Apellis Pharmaceuticals's net margin of -86.98%. Apellis Pharmaceuticals's return on equity of -83.06% beat Macrogenics's return on equity of -60.58%.

Apellis Pharmaceuticals has a consensus price target of $40.35, signalling upside risk potential of 124.29%. On the other hand Macrogenics has an analysts' consensus of $6.00 which suggests that it could grow by 302.69%. Given that Macrogenics has higher upside potential than Apellis Pharmaceuticals, analysts believe Macrogenics is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Macrogenics has a beta of 2.201, suggesting its more volatile than the S&P 500 by 120.129%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Macrogenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Macrogenics pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $212.5M, which are larger than Macrogenics quarterly revenues of $17.7M. Apellis Pharmaceuticals's net income of -$36.4M is lower than Macrogenics's net income of -$15.4M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Macrogenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.85x versus 0.63x for Macrogenics. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -17.11% compared to Apellis Pharmaceuticals's net margin of -103.5%. Apellis Pharmaceuticals's return on equity of -83.06% beat Rhythm Pharmaceuticals's return on equity of -178.94%.

Apellis Pharmaceuticals has a consensus price target of $40.35, signalling upside risk potential of 124.29%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $79.00 which suggests that it could grow by 21.2%. Given that Apellis Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe Apellis Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.362, suggesting its more volatile than the S&P 500 by 136.233%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $212.5M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $41.8M. Apellis Pharmaceuticals's net income of -$36.4M is higher than Rhythm Pharmaceuticals's net income of -$43.3M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.85x versus 30.29x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Y-mAbs Therapeutics has a net margin of -17.11% compared to Apellis Pharmaceuticals's net margin of -25.63%. Apellis Pharmaceuticals's return on equity of -83.06% beat Y-mAbs Therapeutics's return on equity of -30.91%.

Apellis Pharmaceuticals has a consensus price target of $40.35, signalling upside risk potential of 124.29%. On the other hand Y-mAbs Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 314.95%. Given that Y-mAbs Therapeutics has higher upside potential than Apellis Pharmaceuticals, analysts believe Y-mAbs Therapeutics is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Y-mAbs Therapeutics has a beta of 0.531, suggesting its less volatile than the S&P 500 by 46.863%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Y-mAbs Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Y-mAbs Therapeutics pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $212.5M, which are larger than Y-mAbs Therapeutics quarterly revenues of $26.5M. Apellis Pharmaceuticals's net income of -$36.4M is lower than Y-mAbs Therapeutics's net income of -$6.8M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Y-mAbs Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.85x versus 1.96x for Y-mAbs Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.